

Press release 2024-11-26

AcuCort Presented at ISPOR in Barcelona

AcuCort recently participated in the ISPOR Europe scientific conference in Barcelona, where the company presented the results of the study titled "*Swedish Allergists' View on the Role of Cortisone and the Formulation (Tablets or Self-Dissolving Film) for the Treatment of Acute Allergic Reactions.*"

AcuCort has conducted the study "*Swedish Allergists' View on the Role of Cortisone and the Formulation (Tablets or Self-Dissolving Film) for the Treatment of Acute Allergic Reactions*" through interviews with clinically experienced allergists.

The primary objective of the study was to clarify when and to what extent corticosteroids are used in relation to the severity of allergic reactions, as well as the conditions under which patients currently treated with corticosteroid tablets receive treatment in acute situations.

AcuCort was invited to present the study results at the annual scientific conference ISPOR Europe (International Society for Pharmacoeconomics and Outcomes Research), which took place in Barcelona from 17–20 November. This study focuses on the perspectives of physicians.

"The interest in our study results was significant among both physicians and allergists, as well as other commercial stakeholders. We had productive and constructive discussions with potential commercial partners for key European markets," says AcuCort CEO Jonas Jönmark.

Summary of the study results:

- Interviews with allergists in Sweden highlight the significant role of CS in treating severe and acute allergic reactions.
- Factors affecting treatment outcomes in real-life scenarios include patients' lack of access to medication, stress, and the commonality of "inoptimal treatment situations."
- There is a consensus among the experts that a self-dissolving oral film offers advantages over tablets, such as improved adherence and accessibility, despite concerns regarding cost and dosing.

Both physician and patient perspectives

In 2022, AcuCort conducted a survey involving 400 patients in Sweden who had experienced severe allergic reactions.

In the first part of the study, a significant and clear patient need for a medication like Zeqmelit® was identified.

The second part analyzed patients' willingness to pay for a medication like Zeqmelit®. The results revealed that treatment with a self-dissolving oral film is perceived by patients as having a value exceeding traditional tablet treatment by SEK 574 per allergic reaction.

For further information:

Jonas Jönmark, vd, AcuCort AB

Phone: 070 365 5400

E-mail: jonas.jonmark@acucort.se

About AcuCort AB (publ)

AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.